Loading...
Darunavir is generally dosed twice daily (600 mg, with 100 mg of ritonavir) in treatment-experienced patients, but data presented at the 2010 Conference on Retroviruses and Opportunistic Infections suggest that once-daily dosing (800 mg, with 100 mg of ritonavir) might be safe and effective in some of these patients.
In the ODIN trial, Pedro Cahn and colleagues randomized 590 treatment-experienced patients to receive once- or twice-daily ritonavir-boosted darunavir, together with ≥2 nucleoside analogues [Abstract 57]. Of critical importance, none of the patients had evidence of darunavir resistance by genotype, because the following mutations were exclusionary: V11I, V32I, L33F, I47V, I50V, I54L, I54M, T74P, L76V, I84V, …